Events

View All

    Join BIOCYTOGEN at AET (Antibody Engineering & Therapeutics) US 2024

    December 15, 2024
    Share on:

    We’re thrilled to announce our participation as an exhibitor at AET (Antibody Engineering & Therapeutics) US 2024! From December 15th to 18th in San Diego, California, this premier event will bring together leading minds in life sciences for insight exchange, collaboration, and advancement. Unlock the opportunity to be part of discussions on breakthrough topics like bispecifics, ADCs, antibody-based therapies for cancer and neurodegenerative diseases, and much more. Join us as we explore the future of antibody engineering and therapeutics!

     

    What is AET (Antibody Engineering & Therapeutics) US 2024?

    The Antibody Engineering & Therapeutics (AET) global conference series unites scientists and industry leaders to advance antibody science, technology, and collaboration. AET aims to accelerate next-generation antibody development for commercial applications, covering a wide array of topics including antibody discovery, engineering, bispecifics, ADCs, immuno-oncology, AI/ML applications, neurodegenerative diseases, and the tumor microenvironment in antibody therapy.

     

    Event Overview

    Date: December 15th 9:00 am - 18th 5:50 pm

    Venue: Marriott Marquis San Diego

    Event Schedule

    The AET (Antibody Engineering & Therapeutics) US in San Diego, California will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the AET (Antibody Engineering & Therapeutics) US 2024 agenda.

     

    Poster Session

    • Display Time: December 16th, 4:00 PM - December 18th, 2:10 PM PST
    • Presentation Time: December 16th, 6:15 PM - 7:15 PM PST
    • Location: Exhibit Hall

    Poster #22: RenMice Platform: Driving Innovation in Fully Human Antibody Drug Development Across Therapeutic Areas

    We look forward to discussing licensing opportunities for new antibody molecules and antibody discovery platforms with you.

     

    About BIOCYTOGEN

    Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).

    We look forward to seeing you at the AET (Antibody Engineering & Therapeutics) US 2024 in San Diego, California!